Reshma Kewalramani, Vertex CEO (Vertex via YouTube)

Bat­tling a line­up of skep­tics, Ver­tex claims an­oth­er ear­ly clin­i­cal win — this time in kid­ney dis­ease

Ver­tex claimed its sec­ond ear­ly-stage win of the fall Wednes­day, an­nounc­ing pos­i­tive re­sults in a small study on a ge­net­i­cal­ly de­fined form of kid­ney dis­ease.

The 16-pa­tient, Phase II tri­al fo­cused on pa­tients with fo­cal seg­men­tal glomeru­loscle­ro­sis, a rare dis­ease where kid­neys are un­able to fil­ter blood prop­er­ly. Over 13 weeks on an ex­per­i­men­tal pill, the lev­el of pro­tein in the pa­tients’ urine fell by an av­er­age of 47.6%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.